Why was the Azithromycin "for life" trial necessary?
File(s)Maitland-2407000-acceptedversion.docx (21.07 KB)
Accepted version
Author(s)
Maitland, Kathryn
Walker, A Sarah
Type
Journal Article
Abstract
Abstract
Notes
Supplementary Material
Information & Authors
Metrics & Citations
Share
Abstract
In 2009, a cluster-randomized trial showed a 49% reduction in all-cause mortality among Ethiopian children 1 to 9 years of age in the year after mass distribution of a single dose of azithromycin for trachoma prevention — a reduction that was sustained over the following 26 months.1 This remarkable finding led to further multinational cluster-randomized trials examining mass distribution of azithromycin for children 1 to 59 months of age in trachoma-endemic areas of Niger, Tanzania, and Malawi (the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance [MORDOR] trial)2 and such distribution combined with seasonal malaria prophylaxis . . .
Notes
Supplementary Material
Information & Authors
Metrics & Citations
Share
Abstract
In 2009, a cluster-randomized trial showed a 49% reduction in all-cause mortality among Ethiopian children 1 to 9 years of age in the year after mass distribution of a single dose of azithromycin for trachoma prevention — a reduction that was sustained over the following 26 months.1 This remarkable finding led to further multinational cluster-randomized trials examining mass distribution of azithromycin for children 1 to 59 months of age in trachoma-endemic areas of Niger, Tanzania, and Malawi (the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance [MORDOR] trial)2 and such distribution combined with seasonal malaria prophylaxis . . .
Date Issued
2024-08-22
Date Acceptance
2024-08-01
Citation
New England Journal of Medicine, 2024, 391 (8), pp.760-762
ISSN
0028-4793
Publisher
Massachusetts Medical Society
Start Page
760
End Page
762
Journal / Book Title
New England Journal of Medicine
Volume
391
Issue
8
Copyright Statement
© 2024 Massachusetts Medical Society. All rights reserved. This is the author’s accepted manuscript made available under a CC-BY licence in accordance with Imperial’s Research Publications Open Access policy (www.imperial.ac.uk/oa-policy)
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/39167813
Subjects
Anti-Bacterial Agents
Azithromycin
Bacterial Infections
Chemoprevention
Child Mortality
Child, Preschool
Drug Resistance, Bacterial
Humans
Infant
Infant Mortality
Mass Drug Administration
Niger
Randomized Controlled Trials as Topic
Publication Status
Published
Coverage Spatial
United States
Date Publish Online
2024-08-21